Exact Mass: 508.259
Exact Mass Matches: 508.259
Found 500 metabolites which its exact mass value is equals to given mass value 508.259
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Argatroban
Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban. D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
PD 123319
D057911 - Angiotensin Receptor Antagonists > D057912 - Angiotensin II Type 2 Receptor Blockers D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents
Argatroban
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AE - Direct thrombin inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
ID14326
ID14326 is a metabolite of lurasidone. Lurasidone (trade name Latuda) is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 28, 2010 after a review that found that two of the four Phase III clinical trials supported efficacy, while one showed only marginal efficacy and one was not interpretable because of high drop-out rates. (Wikipedia)
1-[[4-(Dimethylamino)-3-methylphenyl]methyl]-5-(2,2-diphenylacetyl)-6,7-dihydro-4H-imidazo[4,5-c]pyridine-6-carboxylic acid
D057911 - Angiotensin Receptor Antagonists > D057912 - Angiotensin II Type 2 Receptor Blockers D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents
Calcitriol phosphate
(R)-N-(2-(1H-Indol-3-yl)-1-(4-(4-methoxybenzyl)-5-phenethyl-4H-1,2,4-triazol-3-yl)ethyl)-2-aminoacetamide
Kushenol M
Kushenol M is a natural product found in Sophora flavescens with data available.
Tanariflavanone A
A hydroxyflavanone with a pyranochromane skeleton that is 3,4,7,8-tetrahydro-2H,6H-pyrano[3,2-g]chromen-6-one substituted by geminal methyl groups at position 2, hydroxy groups at positions 3 and 5 and a phenyl group at position 8 which in turn is substituted by a geranyl group at position 2 and hydroxy groups at positions 3 and 4. Isolated from Macaranga tanarius, it exhibits alleopathic effect.
Petalostemumol
Tanariflavanone C
A tetrahydroxyflavanone that is (2S)-flavanone substituted by hydroxy groups at positions 5,7, 3 and 4, a geranyl group at position 2 and a 2-hydroxy-3-methylbut-3-en-1yl group at position 6. Isolated from Macaranga tanarius, it exhibits radical scavenging activity.
5beta-acetoxy-4beta,11-diangeloyloxy-8,10-dihydroxy-2beta,3beta-epoxy-bisabol-7(14)-ene
1beta,2beta,3beta,4beta,5beta,7alpha-hexahydroxy-spirost-25(27)-en-6-one
methyl 15,16-dideoxy-6alpha,15alpha,17beta-trihydroxy-15,17-oxidospongian-16-carboxylate 6,15,17-triacetate
2beta-acetoxy-1beta,8-diangeloyloxy-3beta,4beta-epoxy-10,11-dihydroxybisabol-7(14)-ene|4beta-acetoxy-5beta,8-diangeloyloxy-10,11-dihydroxy-2beta,3beta-epoxy-bisabol-7(14)-ene
3beta-angeloyloxy-9beta-acetoxy-8beta-angeloyloxy-4alpha,5alpha-dihydroxy-1beta,10alpha-epoxygermacr-11-ene
pregn-5-ene-3,14-beta-dihydroxy-7,20-dione 3-O-beta-glucopyranoside
(12R)-12-cinnamoyloxy-3beta,5-dihydroxy-8,14-seco-5beta,17beta-pregn-6-ene-8,14,20-trione|cynaphyllogenin|Cynaphylloside
(-)-(7S,7S,8R,8S,8R)-4,4-dihydroxy-3,3,5-trimethoxy-4,8-oxy-2,7-cyclo-8,8-sesquineolignan-7-ol
A neolignan isolated from the barks of Machilus robusta.
1beta-acetoxy-2beta,8-diangloyloxy-10,11-dihydroxy-3,4-epoxybisabol-7(14)-ene
14beta-hydroxy-15alpha-(beta-D-glucopyranosyloxy)-17betaH-pregn-4-ene-3,20-dione|stemmoside B
5beta-acetoxy-4beta,10-diangeloyloxy-8,11-dihydroxy-2beta,3beta-epoxy-bisabol-7(14)-ene
3beta-angeloyloxy-9beta-acetoxy-8beta-senecioyloxy-4alpha,5alpha-dihydroxy-1beta,10alpha-epoxygermacr-11-ene
(E)-2,3-dihydro-4-hydroxy-2-(1-hydroxy-1-methylethyl)-7,8-dimethoxy-6-(3,7-dimethyl-2,6-octadienyl)-5H-furo[3,2-b]xanthen-5-one|oliverixanthone
Ajugamarin B3|ajugamarin B3 ((12S)-19-acetoxy-6alpha,12-dihydroxy-1beta-<(2S)-2-methylbutanoyloxy>-4,18-epoxyneo-clerod-13(14)-en-15,16-olide)|ajugamarin B3 [(12S)-19-acetoxy-6alpha,12-dihydroxy-1beta-((2S)-2-methylbutanoyloxy)-4,18-epoxyneo-clerod-13(14)-en-15,16-olide]
21-O-beta-D-Glucosyl-14,21-dihydroxy-14beta-pregn-4-ene-3,20-dione
Phe Thr Asn Lys
Phe Asn Thr Lys
Asn Thr Phe Lys
Ala Lys Gln Tyr
Ala Lys Tyr Gln
Ala Gln Lys Tyr
Ala Gln Tyr Lys
Ala Tyr Lys Gln
Ala Tyr Gln Lys
Cys Lys Lys Met
Cys Lys Met Lys
Cys Met Lys Lys
Asp Ile Val Tyr
Asp Ile Tyr Val
Asp Leu Val Tyr
Asp Leu Tyr Val
Asp Val Ile Tyr
Asp Val Leu Tyr
Asp Val Tyr Ile
Asp Val Tyr Leu
Asp Tyr Ile Val
Asp Tyr Leu Val
Asp Tyr Val Ile
Asp Tyr Val Leu
Glu Phe Ile Thr
Glu Phe Leu Thr
Glu Phe Thr Ile
Glu Phe Thr Leu
Glu Ile Phe Thr
Glu Ile Thr Phe
Glu Leu Phe Thr
Glu Leu Thr Phe
Glu Thr Phe Ile
Glu Thr Phe Leu
Glu Thr Ile Phe
Glu Thr Leu Phe
Glu Val Val Tyr
Glu Val Tyr Val
Glu Tyr Val Val
Phe Glu Ile Thr
Phe Glu Leu Thr
Phe Glu Thr Ile
Phe Glu Thr Leu
Phe Phe Pro Val
Phe Phe Val Pro
Phe Ile Glu Thr
Phe Ile Met Val
Phe Ile Thr Glu
Phe Ile Val Met
Phe Lys Asn Thr
Phe Lys Gln Ser
Phe Lys Ser Gln
Phe Lys Thr Asn
Phe Leu Glu Thr
Phe Leu Met Val
Phe Leu Thr Glu
Phe Leu Val Met
Phe Met Ile Val
Phe Met Leu Val
Phe Met Val Ile
Phe Met Val Leu
Phe Asn Lys Thr
Phe Pro Phe Val
Phe Pro Val Phe
Phe Gln Lys Ser
Phe Gln Ser Lys
Phe Ser Lys Gln
Phe Ser Gln Lys
Phe Thr Glu Ile
Phe Thr Glu Leu
Phe Thr Ile Glu
Phe Thr Lys Asn
Phe Thr Leu Glu
Phe Val Phe Pro
Phe Val Ile Met
Phe Val Leu Met
Phe Val Met Ile
Phe Val Met Leu
Phe Val Pro Phe
His Lys Pro Gln
His Lys Gln Pro
His Pro Lys Gln
His Pro Gln Lys
His Gln Lys Pro
His Gln Pro Lys
Ile Asp Val Tyr
Ile Asp Tyr Val
Ile Glu Phe Thr
Ile Glu Thr Phe
Ile Phe Glu Thr
Ile Phe Met Val
Ile Phe Thr Glu
Ile Phe Val Met
Ile Met Phe Val
Ile Met Val Phe
Ile Thr Glu Phe
Ile Thr Phe Glu
Ile Val Asp Tyr
Ile Val Phe Met
Ile Val Met Phe
Ile Val Tyr Asp
Ile Tyr Asp Val
Ile Tyr Val Asp
Lys Ala Gln Tyr
Lys Ala Tyr Gln
Lys Cys Lys Met
Lys Cys Met Lys
Lys Phe Asn Thr
Lys Phe Gln Ser
Lys Phe Ser Gln
Lys Phe Thr Asn
Lys His Pro Gln
Lys His Gln Pro
Lys Lys Cys Met
Lys Lys Met Cys
Lys Met Cys Lys
Lys Met Lys Cys
Lys Asn Phe Thr
Lys Asn Thr Phe
Lys Pro His Gln
Lys Pro Gln His
Lys Gln Ala Tyr
Lys Gln Phe Ser
Lys Gln Ser Phe
Lys Gln Tyr Ala
Lys Ser Phe Gln
Lys Ser Gln Phe
Lys Thr Phe Asn
Lys Thr Asn Phe
Lys Tyr Ala Gln
Lys Tyr Gln Ala
Leu Asp Val Tyr
Leu Asp Tyr Val
Leu Glu Phe Thr
Leu Glu Thr Phe
Leu Phe Glu Thr
Leu Phe Met Val
Leu Phe Thr Glu
Leu Phe Val Met
Leu Met Phe Val
Leu Met Val Phe
Leu Thr Glu Phe
Leu Thr Phe Glu
Leu Val Asp Tyr
Leu Val Phe Met
Leu Val Met Phe
Leu Val Tyr Asp
Leu Tyr Asp Val
Leu Tyr Val Asp
Met Cys Lys Lys
Met Phe Ile Val
Met Phe Leu Val
Met Phe Val Ile
Met Phe Val Leu
Met Ile Phe Val
Met Ile Val Phe
Met Lys Cys Lys
Met Lys Lys Cys
Met Leu Phe Val
Met Leu Val Phe
Met Val Phe Ile
Met Val Phe Leu
Met Val Ile Phe
Met Val Leu Phe
Asn Phe Lys Thr
Asn Phe Thr Lys
Asn Lys Phe Thr
Asn Lys Thr Phe
Asn Thr Lys Phe
Pro Phe Phe Val
Pro Phe Val Phe
Pro Lys Gln His
Pro Gln His Lys
Pro Gln Lys His
Pro Val Phe Phe
Gln Ala Lys Tyr
Gln Ala Tyr Lys
Gln Phe Lys Ser
Gln Phe Ser Lys
Gln His Lys Pro
Gln His Pro Lys
Gln Lys Ala Tyr
Gln Lys Phe Ser
Gln Lys His Pro
Gln Lys Pro His
Gln Lys Ser Phe
Gln Lys Tyr Ala
Gln Pro His Lys
Gln Pro Lys His
Gln Ser Phe Lys
Gln Ser Lys Phe
Gln Tyr Ala Lys
Gln Tyr Lys Ala
Ser Phe Lys Gln
Ser Phe Gln Lys
Ser Lys Phe Gln
Ser Lys Gln Phe
Ser Gln Phe Lys
Ser Gln Lys Phe
Thr Glu Phe Ile
Thr Glu Phe Leu
Thr Glu Ile Phe
Thr Glu Leu Phe
Thr Phe Glu Ile
Thr Phe Glu Leu
Thr Phe Ile Glu
Thr Phe Lys Asn
Thr Phe Leu Glu
Thr Phe Asn Lys
Thr Ile Glu Phe
Thr Ile Phe Glu
Thr Lys Phe Asn
Thr Lys Asn Phe
Thr Leu Glu Phe
Thr Leu Phe Glu
Thr Asn Phe Lys
Thr Asn Lys Phe
Val Asp Ile Tyr
Val Asp Leu Tyr
Val Asp Tyr Ile
Val Asp Tyr Leu
Val Glu Val Tyr
Val Glu Tyr Val
Val Phe Phe Pro
Val Phe Ile Met
Val Phe Leu Met
Val Phe Met Ile
Val Phe Met Leu
Val Phe Pro Phe
Val Ile Asp Tyr
Val Ile Phe Met
Val Ile Met Phe
Val Ile Tyr Asp
Val Leu Asp Tyr
Val Leu Phe Met
Val Leu Met Phe
Val Leu Tyr Asp
Val Met Phe Ile
Val Met Phe Leu
Val Met Ile Phe
Val Met Leu Phe
Val Pro Phe Phe
Val Val Glu Tyr
Val Val Tyr Glu
Val Tyr Asp Ile
Val Tyr Asp Leu
Val Tyr Glu Val
Val Tyr Ile Asp
Val Tyr Leu Asp
Val Tyr Val Glu
Tyr Ala Lys Gln
Tyr Ala Gln Lys
Tyr Asp Ile Val
Tyr Asp Leu Val
Tyr Asp Val Ile
Tyr Asp Val Leu
Tyr Glu Val Val
Tyr Ile Asp Val
Tyr Ile Val Asp
Tyr Lys Ala Gln
Tyr Lys Gln Ala
Tyr Leu Asp Val
Tyr Leu Val Asp
Tyr Gln Ala Lys
Tyr Gln Lys Ala
Tyr Val Asp Ile
Tyr Val Asp Leu
Tyr Val Glu Val
Tyr Val Ile Asp
Tyr Val Leu Asp
Tyr Val Val Glu
Argatroban Impurity 26
Sodium 2,2-methylene-bis-(4,6-di-tert-butylphenyl)phosphate
(R)-N-(2-(1H-Indol-3-yl)-1-(4-(4-methoxybenzyl)-5-phenethyl-4H-1,2,4-triazol-3-yl)ethyl)-2-aminoacetamide
(5Z)-5-[(2E)-2-[2-(6-hydroxy-6-methylheptan-2-yl)-3-methyl-11-oxo-10,12,13-trioxa-11lambda5-phosphatetracyclo[9.1.1.01,9.03,8]tridecan-7-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
(6S)-1-[4-(dimethylamino)-3-methylbenzyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid
D057911 - Angiotensin Receptor Antagonists > D057912 - Angiotensin II Type 2 Receptor Blockers D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents
1-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-(2-methoxyphenyl)-1-methylurea
1-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-(2-methoxyphenyl)-1-methylurea
2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
2-[(1R,3R,4aR,9aS)-6-[[anilino(oxo)methyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
2-[(1S,3S,4aR,9aS)-6-[[anilino(oxo)methyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
1-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-(2-methoxyphenyl)-1-methylurea
1-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-(2-methoxyphenyl)-1-methylurea
1-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-(2-methoxyphenyl)-1-methylurea
1-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-(2-methoxyphenyl)-1-methylurea
2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-[(2-pyridin-4-ylacetyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-(2-piperidin-1-ylethyl)acetamide
2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-[(2-pyridin-4-ylacetyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-(2-piperidin-1-ylethyl)acetamide
2-[(1S,3S,4aS,9aR)-6-[[anilino(oxo)methyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
2-[(1R,3S,4aR,9aS)-6-[[anilino(oxo)methyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[1-oxo-2-(2-pyridinyl)ethyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
2-[(1S,3R,4aS,9aR)-6-[[anilino(oxo)methyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
2-[(1S,3R,4aR,9aS)-6-[[anilino(oxo)methyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
(1S)-1-[(3-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-7-methoxy-N-propyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
cyclohexyl-[(1R)-1-(hydroxymethyl)-7-methoxy-2-(2-thiazolylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanone
(1S)-2-[(4-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-7-methoxy-N-propan-2-yl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(1R)-N-(4-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-(4-oxanylmethyl)-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]carboxamide
(1R)-N-(3-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-(4-oxanylmethyl)-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]carboxamide
(2S,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2S,3R)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[1-oxo-2-(2-pyridinyl)ethyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[1-oxo-2-(2-pyridinyl)ethyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[1-oxo-2-(2-pyridinyl)ethyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[1-oxo-2-(2-pyridinyl)ethyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[1-oxo-2-(2-pyridinyl)ethyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[1-oxo-2-(2-pyridinyl)ethyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[1-oxo-2-(2-pyridinyl)ethyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
2-[(1R,3R,4aS,9aR)-6-[[anilino(oxo)methyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
2-[(1R,3S,4aS,9aR)-6-[[anilino(oxo)methyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
(1R)-1-[(3-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-7-methoxy-N-propyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
cyclohexyl-[(1S)-1-(hydroxymethyl)-7-methoxy-2-(2-thiazolylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanone
(1R)-2-[(4-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-7-methoxy-N-propan-2-yl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(8-hydroxy-3,7-dimethylocta-2,6-dien-1-yl)-6-(3-methylbut-2-en-1-yl)-3,4-dihydro-2H-1-benzopyran-4-one
1-[[4-(Dimethylamino)-3-methylphenyl]methyl]-5-(2,2-diphenylacetyl)-6,7-dihydro-4H-imidazo[4,5-c]pyridine-6-carboxylic acid
D057911 - Angiotensin Receptor Antagonists > D057912 - Angiotensin II Type 2 Receptor Blockers D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents
MCP110
MCP110 is an inhibitor of Ras/Raf-1 interaction. MCP110 blocks the interaction of Ras with Raf. MCP110 disrupts this interaction might can be used for the research of human tumors[1].